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ABSTRACT 
Background: Baseline clinical variables are prognostic for overall survival (OS) in patients with 
castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents 
targeting bone metastases, such as radium-223, is not established. 
Patients and methods: The radium-223 ALSYMPCA trial enrolled patients with CRPC and 
symptomatic bone metastases. Prognostic potential of baseline variables was assessed using Cox 
models. Percentage changes in biomarker levels from baseline were evaluated during the trial 
period; changes from baseline to week 12 were evaluated for association with OS and surrogacy. 
Results: Eastern Cooperative Oncology Group performance status, total alkaline phosphatase 
(tALP), lactate dehydrogenase (LDH), and prostate-specific antigen (PSA) at baseline were 
associated with OS (P≤0.0003) in the intent-to-treat population (radium-223, N=614; placebo, 
N=307). tALP declined from baseline within 4 weeks after beginning radium-223, by week 12 
declining in 87% of radium-223 and 23% of placebo patients (P<0.001). LDH declined in 51% 
and 34% (P=0.003), whereas PSA declined in 27% and 14% (P=0.160). Mean tALP change 
from baseline was 32.2% decrease with radium-223 and 37.2% increase with placebo. Radium-
223 patients with tALP decline from baseline to week 12 (confirmed ≥3 weeks from week 12) 
had 55% lower risk of death (hazard ratio=0.45; 95% CI 0.34-0.61) versus those with no 
confirmed tALP decline. Proportional treatment effect (PTE) values for tALP, LDH, and PSA 
changes from baseline at week 12 as OS surrogate markers were 0.34 (95% CI: 0-0.746), 0.07 
(95% CI: 0-0.211), and 0 (95% CI: 0-0.082), respectively.  
Conclusions: Significant tALP declines (versus placebo) occurred as early as 4 weeks after 
beginning radium-223 therapy. tALP or LDH declines at 12 weeks correlated with longer OS, 
but did not meet statistical surrogacy requirements. Dynamic changes in tALP and LDH during 
radium-223 treatments may be useful to monitor, but do not serve as surrogates for survival. 
 
 
Key message  
In an exploratory analysis of patients with CRPC and bone metastases enrolled in the phase 3 
ALSYMPCA trial, tALP was an early pharmacodynamic marker with declines significantly 
associated with longer survival. Monitoring biomarker levels during treatment may be useful in 
managing radium-223 therapy, but changes in tALP do not meet statistical requirements as a 
surrogate for survival.  
INTRODUCTION  
For individual patients with metastatic castration-resistant prostate cancer (mCRPC), prognostic 
models based on baseline clinical characteristics may be used to predict survival but are not 
currently used to monitor responses to therapy [1-5]. Serial bone scans [6] and advanced imaging 
methods [7] may serve this purpose, but simpler, less invasive, less expensive methods are 
needed to dynamically monitor therapy and inform decisions regarding treatment modification 
[8]. A surrogate marker that predicted overall survival (OS) in individual patients would be 
particularly useful in decisions regarding treatment modification [9]. 
Surrogacy requirements for OS in advanced prostate cancer were met for patients receiving 
docetaxel therapy by prostate-specific antigen (PSA) decreases >30% after 3 weeks of treatment 
in the SWOG 99-16 [10] and TAX327 [3] trials, and for patients receiving abiraterone acetate 
plus prednisone therapy or prednisone alone by the number of circulating tumor cells (CTC) and 
lactate dehydrogenase (LDH) levels after 12 weeks of treatment [11]. These surrogates may 
eventually aid in monitoring therapy with these agents, but further clinical investigation and 
validation are required [10, 12]. For approximately 70% of advanced prostate cancer patients 
with bone metastases [8], bone-related markers (eg, total alkaline phosphatase [tALP]) are 
prognostic for OS [13-15] and tALP changes may be an early indicator of bone progression [8]. 
Both PSA and tALP changes are closely associated with survival, but PSA levels do not provide 
accurate information regarding extent of skeletal metastases or treatment effects on disease 
progression in bone. Therefore, tALP changes may correlate better with OS than PSA [16, 17].  
The phase 3 ALSYMPCA trial established radium-223 efficacy and safety in CRPC patients 
with bone metastases [18, 19]. With radium-223, versus placebo, OS improved significantly 
(median 14.9 vs 11.3 mo; hazard ratio [HR]=0.70; 95% confidence interval [CI]: 0.58, 0.83). 
Time to first symptomatic skeletal event was significantly prolonged (median 15.6 vs 9.8 mo; 
HR=0.66; 95% CI: 0.52-0.83), and secondary end points (including time to tALP increase, tALP 
response rate, and tALP normalization rate) favored radium-223 treatment [18, 19]. 
For mCRPC patients treated with radium-223, tALP changes properly established as a surrogate 
for survival could optimize treatment, allowing quick change of direction of therapies to patients 
most likely to benefit from such changes. Thus, exploratory analyses were conducted from 
ALSYMPCA to evaluate the treatment effect of radium-223 on changes in tALP, LDH, and PSA 
levels and assess their prognostic and predictive value. 
METHODS  
ALSYMPCA compared efficacy and safety of radium-223 versus placebo, each plus best 
standard of care, in CRPC patients with symptomatic bone metastases [18]. Randomized patients 
(2:1) received 6 intravenous injections of radium-223 (50 kBq/kg IV [55 kBq/kg IV following 
US National Institutes of Standards and Technology update]) [20] or matching placebo, 1 
injection every 4 weeks. The primary end point was OS.  
Univariate and multivariate analyses with Cox proportional hazards models assessed the 
potential prognostic value for survival of selected baseline variables in placebo patients, radium-
223 patients, and the intent-to-treat (ITT) population. Selected variables included prior docetaxel, 
prior hormone therapy, hemoglobin, serum albumin, tALP, PSA, LDH, Eastern Cooperative 
Oncology Group performance status (ECOG PS), opiate use, and age at study entry [4]. Kaplan-
Meier analysis, after tertile grouping using baseline values, further illustrated the association of 
baseline tALP, PSA, and LDH with OS for radium-223 and placebo patients.  
Changes from baseline in tALP, PSA, and LDH were assessed as least-squares mean percentage 
change at week 12, the halfway point of treatment, allowing consistency in protocol-defined 
timing of tALP and PSA measurements. Waterfall plots of maximum percentage change in 
tALP, LDH, and PSA from baseline to week 12 for each patient illustrated the magnitude of 
treatment effect. Dynamics of mean percentage change from baseline in biomarker levels, at 
each treatment visit and follow-up visits 12 and 24 weeks after last study-drug dose, were 
evaluated. OS by confirmed tALP or LDH decline at week 12 (decline confirmed ≥3 weeks from 
week 12) was evaluated. The relationship of relative risk of death to percentage changes from 
baseline at week 12 (last observation carried forward) was assessed using Cox proportional 
hazards modeling, including all baseline covariates.  
Changes in tALP, PSA, and LDH from baseline to week 12 were evaluated as potential measures 
of OS surrogacy, as defined by Prentice [9], and quantified as a proportional treatment effect 
(PTE) [12]. PTE describes how much of the treatment effect on OS is explained by biomarker 
changes. PTE was calculated as 1 minus the ratio of (a) HR in the Cox proportional hazards 
regression model for survival with treatment (radium-223) plus the surrogate marker (tALP, 
PSA, LDH) to (b) that with treatment alone. Perfect surrogacy would be indicated by PTE=1; no 
surrogacy, by PTE=0. CIs were calculated according to Lin et al [12], with a strong degree of 
surrogacy suggested if the 95% CI lower bound exceeded 0.5.   
RESULTS 
Baseline Prognostic Factors 
Multivariate analysis of baseline prognostic values as continuous variables was performed for 
placebo and radium-223 patients separately and for the entire ITT population (Table 1). For 
radium-223 patients, poor baseline ECOG PS and elevated baseline values for LDH, tALP, and 
PSA were associated with highest risk of death; for placebo patients, elevated baseline values for 
LDH and tALP were significantly associated with an increased risk of death. For the overall ITT 
population, opiate use was an additional significant baseline prognostic variable for OS. Kaplan-
Meier analysis showed longer median survival among radium-223 patients in the lowest tALP 
tertile (≤131 U/L), versus those in the highest tertile (≥334 U/L) (23.9 vs 10.2 mo); no overlap in 
the 95% CIs indicated a consistent trend across subgroups (supplementary Figure S1A). Placebo 
patients in the lowest (≤153 U/L) versus highest (≥360 U/L) tALP tertile also survived longer 
(median 18.8 vs 7.5 mo) (supplementary Figure S1B). Similarly, longer survival was seen for 
radium-223 and placebo patients with lower versus higher baseline LDH (supplementary Figure 
S1 C and D, respectively) and PSA values (data not shown).  
Posttreatment Changes From Baseline 
Changes from baseline were assessed at week 12 for tALP, LDH, and PSA for patients with 
baseline and week 12 determinations (supplementary Figure S2). tALP decreased from baseline 
in 87% (433/497) of radium-223 patients versus 23% (49/211) of placebo patients (P<0.001). 
For LDH, 51% (242/473) radium-223 and 34% (70/206) placebo patients showed a decrease 
(P=0.003). PSA declined in 27% (135/493) of radium-223 and 14% (30/210) of placebo patients 
(P=0.160) (supplementary Table S1). Waterfall plots, showing maximum percentage change in 
tALP and LDH at any time from baseline to week 12 for each patient in radium-223 and placebo 
groups, illustrated the between-group magnitude of difference in tALP response (supplementary 
Figure S3A) and a similarity in LDH response (supplementary Figure S3B), revealing a 
stronger association of tALP versus LDH declines with radium-223 treatment. No apparent 
difference was seen in waterfall plots of PSA response for radium-223 versus placebo (not 
shown). 
Mean percentage change from baseline in tALP and LDH for radium-223 and placebo patients 
through 24 weeks of radium-223 treatment and follow-up are shown in Figure 1 A and B. With 
radium-223, tALP decreases occurred as early as 4 weeks after treatment initiation, remained 
consistently low until treatment completion at 24 weeks, and remained significantly lower versus 
placebo patients at all time points to 46 weeks (P<0.001) (Figure 1A). With placebo, tALP 
increased continuously through treatment and posttreatment follow-up. LDH levels for 
radium-223 patients were significantly lower versus placebo patients throughout most of the 24-
week treatment period, but remained above baseline and increased through posttreatment follow-
up at a rate similar to the placebo group rate (Figure 1B). 
Relationship of Posttreatment Changes to OS and Surrogacy 
In an exploratory analysis, radium-223 patients with confirmed tALP or LDH decline from 
baseline at week 12 survived longer than those with no confirmed decline (Figure 2 A and B). 
Among 497 patients with tALP values determined at baseline and week 12, 400 patients with a 
confirmed tALP decline had a median survival of 17.8 months and 55% lower risk of death 
(HR=0.45; 95% CI: 0.34-0.61; P<0.0001) versus 97 patients with no confirmed tALP decline 
(median survival, 10.4 mo) (Figure 2A). Baseline characteristics were similar between patients 
with and those without confirmed decline. Although heavily weighted at the lower end by 
number of patients experiencing a tALP decrease, Cox regression modeling shows a near-linear 
relationship between percentage change in tALP from baseline (increase or decrease) at week 12 
and risk of death, relative to no change in tALP (Figure 3A). Similarly, 196 radium-223 patients 
with an LDH decline from baseline to week 12 survived a median of 19.5 months and had a 45% 
lower risk of death (HR=0.55; 95% CI: 0.42-0.73; P<0.0001) versus 277 patients with no LDH 
decline (median survival, 14.5 mo) (Figure 2B). Greater LDH increases, however, were 
associated with exponentially rapid increase in risk of death. Patients with a 300% to 400% 
increase in LDH at week 12 had an approximately 7- to 14-fold greater risk than those with no 
LDH change (Figure 3B). In contrast, among 493 radium-223 patients with PSA values 
determined at baseline and week 12, PSA increased in 358 (73%) patients, often by factors of 10-
fold or more. Multivariate analysis of the correlation between OS and PSA changes at week 12 
showed that the impact of PSA changes at week 12 on risk of death was negligible (Figure 3C). 
PTE values based on Cox regression models for tALP, LDH, and PSA changes from baseline at 
week 12 as surrogate markers of survival were 0.34 (95% CI: 0-0.746), 0.07 (95% CI: 0-0.211), 
and 0 (95% CI: 0-0.082), respectively. tALP had the highest PTE, but only modest surrogacy; a 
PTE=0.34 indicates that the tALP decrease accounted for about 34% of the survival benefit from 
radium-223 treatment. 
DISCUSSION  
Multivariate analysis showed that elevated baseline tALP and LDH levels were associated with 
higher risk of death, compared with other factors, in placebo patients who did not receive 
radium-223 treatment, as well as in radium-223‒treated patients and the entire ITT population. 
Our findings for mCRPC patients with bone-only disease are consistent with similar studies in 
less defined populations and highlight the relative importance of tALP in this setting [2-5].  
In ALSYMPCA, radium-223 treatment prolonged survival for patients with CRPC and bone-
only metastases [18]. In this post hoc analysis, we report confirmed tALP declines in 80% of 
evaluable patients after 12 weeks of receiving radium-223 and their association with decreased 
risk of death, suggesting that changes in tALP could potentially be a surrogate for survival useful 
in managing patients receiving radium-223 therapy. The ALSYMPCA findings meet the 
requirements for a surrogacy analysis as described by Prentice [9]. PTE surrogacy analysis 
showed tALP decreases at 12 weeks from baseline to be a moderate predictor of survival, with 
PTE=0.34 and a broad CI (0.0, 0.746). The analysis also indicated that radium-223 effects on 
LDH or PSA contributed little or nothing to the radium-223–associated survival benefit. Our 
tALP findings were consistent with those reported in TAX327, which showed an association 
with OS but could not establish surrogacy for tALP changes in patients with bone metastases 
[16]. 
Responses to chemotherapy are likely related to a combination of factors: the patient’s 
underlying physical condition and probably other factors reflected or not in biomarker levels, 
such as pain score and visceral organ involvement. Scher and colleagues [11], in their phase 3 
study of abiraterone acetate–prednisone, reported a high level of surrogacy for a biomarker panel 
consisting of the combination of circulating tumor cell (CTC) count and LDH level at 12 weeks. 
They used Prentice criteria [9] to establish relative surrogacy, but did not assess PTE. The CTC-
LDH combination was superior to CTC or LDH alone or to CTC combination with any other 
biomarkers, including tALP decreases and ≥30% or ≥50% PSA decreases. Future assessments of 
the validity of markers in predicting effectiveness of chemotherapy may be more successful 
when combinations of factors are considered. 
Limitations in our study influenced our conclusions: The exploratory analysis was not included 
in the original ALSYMPCA study plan; other relevant bone markers and markers such as CTCs, 
not prospectively determined in this phase 3 study, could not be considered. We analyzed only 
biomarker level decreases from baseline to 12 weeks. If we considered specific rates of decline, 
as in the PSA studies, we may have arrived at a higher PTE value, but the patient number in each 
group may have been inadequate for statistical analysis. We evaluated markers individually, not 
in combination; the proportion of patients showing LDH and PSA decreases did not appear to 
justify the more extensive analysis. Future prospective studies addressing these limitations may 
identify more promising candidates for surrogacy. With these caveats, we found that changes in 
tALP, LDH, and PSA levels after 12 weeks of treatment are not surrogates for survival for 
patients with CRPC and bone metastases treated with radium-223. The effective course of 
radium-223 treatment in ALSYMPCA was 24 weeks, with 6 cycles given at 4-week intervals. 
Using biomarker changes, particularly rising PSA levels, to make decisions about continuing 
radium-223 presents a substantial risk that a large fraction of patients who may benefit will be 
denied effective treatment. Monitoring biomarkers during treatment may have benefit as an 
indication for radiologic evaluation of disease status [8]. 
The observed tALP changes with treatment raise questions about radium-223 treatment duration 
and underline the need for a reliable marker of radium-223 efficacy. In ALSYMPCA with 
radium-223, the rapid and sustained tALP declines and the increasing tALP suppression with 
continued therapy reflected the radionuclide mechanism of action in the bone microenvironment, 
consistent with rapid and progressive inhibition of ALP production by osteoblasts. Dynamic 
profiles of both tALP and LDH levels during the study suggest that treatment durations more 
than 24 weeks should be tested. Although we could not determine whether tALP changes were a 
direct effect on cancer cells or on osteoblasts, preclinical studies suggest that tALP is a marker of 
pharmacodynamic effect and that radium-223 impacts both osteoblasts and tumor cells [21, 22]. 
In a human prostate cancer model, characterized by osteoblastic growth, PSA production, and 
systemic metastases when inoculated into the bone marrow cavity, radium-223 inhibited disease 
progression, reduced tumor volume, and decreased areas of tumor in tumor-bearing tibias. 
Tumor-induced osteoblastic bone growth was suppressed and normal architecture was 
maintained, leading to reduced bone volume in tumor-bearing bone. Radium-223 induced 
double-strand DNA breaks in tumor cells and osteoclasts, consistent with potent radiation effects 
of radium-223 in the tumor microenvironment [21, 22]. Such models in prostate cancer, and 
others in breast cancer [23], are important in addressing questions about radium-223 mode of 
action in cancer patients. 
In conclusion, significant tALP declines (versus placebo) occurred as early as 4 weeks after 
initiation of radium-223 therapy. tALP or LDH decline at 12 weeks correlated with longer OS, 
but did not meet statistical surrogacy requirements. Changes in tALP and LDH are dynamic 
during radium-223 treatments and may be useful to monitor, but do not serve as surrogates for 
survival. 
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 FIGURE LEGENDS  
Figure 1. tALP and LDH dynamics in the ITT population. Mean percentage change in (A) 
baseline tALP and (B) baseline LDH at the end of each treatment cycle (6 cycles) and two 
follow-up visits. Six patients in the radium-223 arm and 1 in the placebo arm did not have 
baseline LDH determinations and were excluded from this analysis. ITT, intent to treat; LDH, 
lactate dehydrogenase; tALP, total alkaline phosphatase.  
Figure 2 Overall survival in the radium-223 cohort with and without a confirmed decline in (A) 
baseline tALP and (B) baseline LDH at week 12. Confirmed decline was defined as any decrease 
from baseline at week 12, confirmed ≥3 weeks later.  LDH, lactate dehydrogenase; tALP, total 
alkaline phosphatase. 
Figure 3. Relationship between percentage change in (A) tALP, (B) LDH, and (C) PSA levels 
from baseline and risk of death relative to no change in tALP, LDH, or PSA in the ITT 
population with baseline marker analyses. The red lines in (A) define the area of decreasing risk 
of death with decreases in tALP from their baseline level. To make (C) PSA comparable to (A) 
tALP, its x axis was truncated to include only patients with PSA percentage changes from 
baseline between -100% and 300%; 46 of 910 (5.1%) patients with percentage changes in PSA 
>300% were excluded. LDH, lactate dehydrogenase; PSA, prostate-specific antigen; tALP, total 
alkaline phosphatase. 
 
  
 
 
Figure 1A. Mean percentage change in tALP levels from baseline after each cycle of treatment (6 cycles) and 
at 2 follow-up visits (ITT population)  
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Figure 1B. Mean percentage change in LDH levels from baseline after each cycle of treatment (6 cycles) and 
at 2 follow-up visits (ITT population)  
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Figure 2A. Overall survival in radium-223 patients with and without a confirmed tALP decline at week 12.  
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Figure 2B. Overall survival in radium-223 cohort with and without a confirmed decline in baseline LDH at 
week 12.  
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Figure 3A. Relationship between percentage tALP change from baseline and risk of death.  
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Figure 3B. Relationship between percentage change of LDH from baseline and risk of death.  
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Figure 3C. Relationship between percentage change of PSA from baseline and risk of death.  
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Table 1. Multivariate analysis of the correlation of baseline covariates with overall survival
a
 
Baseline variable HRb P valuec 
Placebo patients 
Albumin 0.970 0.0652 
ECOG PS (≥ 2 vs 0 or 1) 1.441 0.0839 
Log LDH
d
 2.632  0.0043 
Log tALP
d
 2.332 <0.0001 
Log PSA
d
 1.250 0.0569 
Age 1.009 0.3804 
Radium-223 patients   
Albumin 0.972 0.0224 
ECOG PS (≥ 2 vs 0 or 1) 1.775 0.0002 
Log LDH
d
 4.244 <0.0001 
Log tALP
d
 1.857 0.0001 
Log PSA
d
 1.498 <0.0001 
Age 1.018 0.0172 
Overall ITT population  
Randomized treatment group 0.779 0.0074 
Albumin 0.974 0.0069 
ECOG PS (≥ 2 vs 0 or 1) 1.576 0.0003 
Log LDH
d
 3.407 <0.0001 
Log tALP
d
 2.017 <0.0001 
Log PSA
d
 1.405 <0.0001 
Age 1.016 0.0080 
Opiate use (yes or no) 1.214 0.0379 
a
Baseline factors significantly associated with survival by univariate analysis were included in 
the multivariate analysis. 
b
HRs are relative risk for a 1-unit increase in the baseline variable for those without log 
transformation, or a 10-fold increase for those with log transformation.
 
c
Based on Cox proportional hazards model. 
d
Log transformation was performed for baseline variables with heavily skewed distributions. 
ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; LDH, 
lactate dehydrogenase; ITT, intent-to-treat; PSA, prostate-specific antigen; tALP, total alkaline 
phosphatase. 
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SUPPLEMENTARY MATERIALS 
 
 
Study Conduct and Patients 
 
ALSYMPCA compared efficacy and safety of radium-223 versus placebo, each plus best 
standard of care, in castration-resistant prostate cancer (CRPC) patients with symptomatic bone 
metastases (Parker et al. N Engl J Med 2013; 369: 213-223). Randomized patients (2:1) received 
6 intravenous injections of radium-223 (50 kBq/kg IV [55 kBq/kg IV following US National 
Institutes of Standards and Technology update]) (Zimmerman et al. J Res Natl Stand Technol 
2015; 120: 37-57) or matching placebo, 1 injection every 4 weeks. The primary end point was 
overall survival (OS). An exploratory analysis was performed to assess the prognostic value for 
OS of selected baseline variables and the potential predictive value for OS of changes in total 
alkaline phosphatase (tALP), lactate dehydrogenase (LDH), and prostate-specific antigen (PSA) 
during treatment with radium-223. 
Prognostic Value of Baseline Variables 
Univariate and multivariate analyses with Cox proportional hazards models were used to assess 
the potential prognostic value of selected baseline variables for survival for placebo patients, 
radium-223 patients, and the intent-to-treat (ITT) population (separate analyses of baseline 
biomarker values for treatment interaction showed no significant treatment-covariate interactions 
at the 5% level). Selected variables included prior docetaxel, prior hormone therapy, 
hemoglobin, serum albumin, tALP, PSA, LDH, Eastern Cooperative Oncology Group 
performance status (ECOG PS), opiate use, and age at study entry (Halabi et al. J Natl Cancer 
Inst 2013; 105: 1729-1737). Analyses used continuous variables with no cutoffs. ALSYMPCA 
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laboratory analyses were conducted at each participating institution. Kaplan-Meier analysis, after 
tertile grouping using baseline values, further illustrated the association of baseline tALP, PSA, 
and LDH with OS for radium-223 and placebo patients. 
Results of the multivariate analysis are described in the main text of the manuscript and in Table 
1. For placebo patients, multivariate analysis showed that elevated baseline values for tALP and 
LDH were significantly associated with an increased risk of death. No significant association 
was seen between risk of death and age at study entry or baseline ECOG PS, albumin, or PSA 
(supplementary Table S1). For radium-223 patients, baseline albumin, ECOG PS, LDH, tALP, 
PSA, and age were associated with survival; highest risk of death was associated with poor 
ECOG PS and elevated baseline LDH, tALP, and PSA. For the overall ITT population, opiate 
use was an additional significant baseline prognostic variable for OS.  
Kaplan-Meier analysis for tALP showed longer survival among radium-223 patients in the 
lowest tALP tertile (≤131 U/L), median 23.9 months, versus those in the highest tertile (≥334 
U/L), median 10.2 months; no overlap in the 95% CIs indicated a consistent trend across 
subgroups (supplementary Figure S1A). Placebo patients in the lowest (≤153 U/L) versus 
highest (≥360 U/L) tALP tertile also had longer median survival (18.8 vs 7.5 mo), supporting 
prognostic value of baseline tALP for survival (supplementary Figure S1B). Overall, radium-
223 patients had longer OS versus placebo patients across tertile subgroups. Similarly, longer 
survival appeared with lower versus higher baseline LDH among radium-223 (18.4 vs 9.1 mo) 
and placebo (13.7 vs 8.1 mo) patients (supplementary Figures S1 C and D). PSA showed longer 
survival for radium-223 and placebo patients in the lowest versus upper 2 tertiles, but with 
considerable overlap in CIs for each group (not shown). 
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Posttreatment Changes From Baseline 
Changes from baseline in tALP, PSA, and LDH were assessed as least-squares mean percentage 
change at week 12, the halfway point of treatment, allowing consistency in protocol-defined 
timing of tALP and PSA measurements. Changes from baseline were assessed at week 12 for 
tALP, LDH, and PSA for patients with baseline and week 12 determinations (supplementary 
Figure S2). For tALP, 87% (433/497) of radium-223 patients had a decrease from baseline, 
versus 23% (49/211) of placebo patients. Radium-223 patients showed a mean 32.2% tALP 
decrease, whereas placebo patients showed a mean 37.2% tALP increase (P<0.001; 
supplementary Table S1). For LDH, the difference between radium-223 and placebo patients 
was more modest, with 51% (242/473) and 34% (70/206), respectively, showing a decrease; the 
mean change was an increase for both groups, 7.3% and 20.8%, respectively (P=0.003; 
supplementary Table S1). PSA declined in 27% (135/493) of radium-223 and 14% (30/210) of 
placebo patients, with mean increases of 83.3% and 543.8%, respectively (P=0.160; 
supplementary Table S1) The magnitude of the difference in tALP response between the 
radium-223 and placebo patients  is shown in the waterfall plot of maximum change in tALP 
occurring at any time from baseline to week 12 (supplementary Figure S3A), This contrasts with 
the similarity of the waterfall plot of maximum LDH response between the radium-223 and 
placebo populations (supplementary Figure S3B). 
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Supplementary Table S1. tALP, LDH, and PSA mean percentage change from baseline at  
week 12  
 
 
Radium-223 
(N = 614) 
Placebo 
(N = 307) P valuea 
Decrease from 
baseline, 
nb/nc (%) 
% changed 
(SE) 
Decrease from 
baseline, 
nb/nc (%) 
% changed 
(SE) 
 
tALP 433/497 (87) -32.2 (1.80) 49/211 (23) 37.2 (2.77) <0.001 
LDH 242/473 (51) 7.3 (2.37) 70/206 (34) 20.8 (3.54) 0.003 
PSA 135/493 (27) 83.3 (152) 30/210 (14) 543.8 (234) 0.160 
aFrom ANCOVA adjusting for the binary stratification factors, total ALP, current use of bisphosphonates and prior use of 
docetaxel 
bNumber of patients with a decrease from baseline and at week 12 
cNumber of patients with measurements at baseline and week 12 
dLeast squares mean 
LDH, lactate dehydrogenase; PSA, prostate-specific antigen; SE, standard error of the mean; tALP, total alkaline phosphatase.  
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Supplementary Figure S1. Overall survival by tertiles in the (A, C) ITT radium-223 and (B, D) 
placebo patients as a function of (A, B) baseline tALP and (C, D) baseline LDH. Patients who 
did not experience an event are censored at the last date on which they were known to be alive. 
Six patients in the radium-223 arm and 1 in the placebo arm did not have baseline LDH 
determinations and were excluded from this analysis. ITT, intent-to-treat; LDH, lactate 
dehydrogenase; min, minimum; max, maximum; tALP, total alkaline phosphatase.  
 
Supplementary Figure S1A. Overall survival by tertiles of baseline tALP in the radium-223 
cohort.  
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Supplementary Figure S1B. Overall survival by tertiles of baseline tALP in the placebo cohort. 
  
 
 
 
 
 
Supplementary Figure S1C. Overall survival by tertiles of baseline LDH in the radium-223 
cohort. 
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Supplementary Figure S1D. Overall survival by tertiles of baseline LDH in the placebo cohort.  
 
 
 
 
 
 
Supplementary Figure S2. Patient dispositions for the ALSYMPCA post hoc biomarker 
analyses. LDH, lactate dehydrogenase; ITT, intent-to-treat; PSA = prostate-specific antigen; 
tALP, total alkaline phosphatase. 
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Supplementary Figure S3: Maximum percentage change from baseline to week 12 for (A) 
tALP and (B) LDH in the placebo and radium-223 cohorts. Includes all patients with tALP and 
LDH determinations at baseline and week 12. LDH, lactate dehydrogenase; tALP, total alkaline 
phosphatase. 
 
Supplementary Figure S3A. Maximum percentage change in tALP from baseline to week 12 in 
the placebo and radium-223 cohorts  
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Supplementary Figure S3B. Maximum percentage change in LDH from baseline to week 12 in 
the placebo and radium-223 cohorts.  
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Supplementary Table S1. tALP, LDH, and PSA mean percentage change from baseline at  
week 12  
 
 
Radium-223 
(N = 614) 
Placebo 
(N = 307) P value
a
 
Decrease from 
baseline, 
n
b
/n
c 
(%) 
% change
d
 
(SE) 
Decrease from 
baseline, 
n
b
/n
c
 (%) 
% change
d
 
(SE) 
 
tALP 433/497 (87) -32.2 (1.80) 49/211 (23) 37.2 (2.77) <0.001 
LDH 242/473 (51) 7.3 (2.37) 70/206 (34) 20.8 (3.54) 0.003 
PSA 135/493 (27) 83.3 (152) 30/210 (14) 543.8 (234) 0.160 
aFrom ANCOVA adjusting for the binary stratification factors, total ALP, current use of bisphosphonates and prior use of 
docetaxel 
bNumber of patients with a decrease from baseline and at week 12 
cNumber of patients with measurements at baseline and week 12 
dLeast squares mean 
LDH, lactate dehydrogenase; PSA, prostate-specific antigen; SE, standard error of the mean; tALP, total alkaline phosphatase. 
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ALSYMPCA ITT Population
• 614 radium-223 patients
• 307 placebo patients
tALP
• 614 radium-223
• 307 placebo
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• 306 placebo
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• 400 radium-223
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• 497 radium-223
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Decrease in biomarker level
from baseline at week 12  
Baseline biomarker 
analyses performed
Baseline and week 12
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LDH
• 473 radium-223
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• 493 radium-223
• 210 placebo
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• 433 radium-223
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LDH
• 242 radium-223
• 70 placebo
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• 135 radium-223
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confirmed 3 weeks later –
radium-223 patients only   
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